Globus Medical (GMED) Q1 FY26 earnings call: guidance and Q&A

Why was full-year revenue guidance reaffirmed despite a Q1 beat? Are there incremental headwinds or is it conservatism?

Management expressed confidence in the guidance, noting it's still early in the year. Factors influencing the decision include the strategic shift in Enabling Technologies towards leases/rentals (impacting upfront revenue recognition) and the expected lumpiness in Nevro's revenue.

“No. Thanks for the question. When we think about guidance, I guess our main point in reiterating guidance is that we feel confident in our numbers. We feel confident with what we've done and been able to achieve in Q1. And feel confident in terms of the rest of the year from a guidance perspective.”

asked by Unknown Analyst · answered by Kyle Kline

How is Globus Medical delivering strong results, particularly with the altered approach in Enabling Technologies, while maintaining core strategies?

The core implant strategy (rep recruiting, new product innovation, robotic pull-through) remains unchanged. The key alteration is in Enabling Technologies, where flexibility in capital acquisition (leases/rentals) is prioritized to drive implant and recurring revenue. Strong U.S. Spine performance and improved International Spine (post-supply chain issues) are also contributing factors.

“As you think about what we're doing, the business, our strategy as it relates to implants really hasn't changed with rep recruiting new product innovation, robotic pull-through. The thing that we're really slightly altering sits on the enabling tech side.”

asked by Shagun Singh Chadha · answered by Keith Pfeil

What are the sources of the significant EPS guidance raise, and why was the top-line revenue guidance not also raised?

EPS upside is driven by durable gross margin expansion from manufacturing and supply chain initiatives, along with OpEx synergy actions and leverage from scaling the business. Revenue guidance was not raised due to the early stage of the year, the impact of the Enabling Technologies mix shift, and anticipated lumpiness in Nevro's revenue.

“As I think about the top line, and Kyle mentioned earlier, we remain confident in the parts and pieces of our business. Our base -- the legacy Base Globus business is performing at a high level. As I think about revenue and why wouldn't raise it at the top line, it's still early in the year, number one.”

asked by Matthew Taylor · answered by Keith Pfeil

What is the current demand environment for robotic platforms, and how are competitive dynamics evolving?

Management sees a healthy robot market with a large pipeline, though the mix is shifting towards leases and rentals. Competition, primarily from Medtronic, has elongated deal closing times as hospitals evaluate multiple offerings. However, ExcelsiusGPS remains well-positioned due to its ground-up design, broad FDA clearances, and unique features.

“I would say that the speed to closing deals has elongated a bit because what I see happening is hospitals are still -- they're now requiring everyone to go back and look at all the competitive offerings that are out there.”

asked by Matthew Miksic · answered by Keith Pfeil

Will Nevro's performance worsen before it improves, given the Q1 sequential decline?

Management expects Nevro's performance will likely 'get a little bit worse before it gets better' following the Q1 lumpiness. They anticipate a return to historical run rate revenue late in the second half of the year as new sales associates are trained and integrated.

“My expectation is likely that it will probably get a little bit worse before it gets better. And then I'd point you to Keith's remarks of expecting to get back to -- in the direction of historical norms late in the back half of the year.”

asked by Ryan Zimmerman · answered by Kyle Kline

How much of U.S. Spine growth comes from market share gains versus underlying market growth, and what is the health of the market?

The majority of U.S. Spine growth is attributed to market share gains. Management estimates the underlying market is growing approximately 3%, indicating that Globus Medical's growth significantly outpaces the market due to its share-taking strategy.

“I would say that the majority of our growth is really coming from share gains. We don't spend a lot of time talking or looking into research in terms of how the market is performing, but I would say that the market probably growing 3%, give or take.”

asked by David Saxon · answered by Keith Pfeil